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Other names: AIS; DHTR; HUMARA; KD; NR3C4; 
RP11-383C12.1; SBMA; SMAX1; TFM 
Location: Xq12 
Local order:  Eukaryota; Metazoa; Chordata; Craniata; 
Vertebrata; Euteleostomi; Mammalia; Eutheria; 
Euarchontoglires; Primates; Haplorrhini; Catarrhini; 
Hominidae; Homo. 
 
Probe(s) - Courtesy Mariano Rocchi, Resources for Molecular 
Cytogenetics. 
Note: (dihydrotestosterone receptor; testicular 
feminization; spinal and bulbar muscular atrophy; 
Kennedy disease). (1 copy in males; 1 functional 
copy/cell in females due to X-inactivation). 
DNA/RNA 
Description 
180 kb gene consisting of 8 exons. 
Transcription 
4,314 bp mRNA, 2,762 bp open reading frame. 
Protein 
Description 
919 amino acids (NCBI: P10275), MW = 99,187.57  
daltons; -1.5 charge with an isoelectric pt = 6.3797; 
10.6 kb AR transcript (NCBI: NM_000044 - partial 
sequence): 1.1kb 5' Untranslated Region (UTR) 
followed by the 2.7 kb Open Reading Frame (ORF) 
followed by the 6.8kb 3' UTR. 
AR: AR isoform 1 [Homo sapiens] NP_000035 920 aa. 
AR45: AR isoform 2 [Homo sapiens] NP_001011645 
388 aa. 
The AR coding sequence contains variable poly-
aminoacid repeats in the amino-terminal domain:  
1. poly-glutamine (CAG: Glu-Q): avg 22 repeats with 
normal polymorphic range from 8 to 35, shorter (<18) 
associated with increased AR transactivation and 
prostate cancer risk. CAG repeats in spinal and bulbar 
muscular atrophy patients range from 38 to 62. 
2. poly-proline (Pro-P): avg 8. 
3. poly-glycine (GGC: Gly-G): avg 23, with normal 
range from 10 to 31. 
Expression 
Embryonic tissue, prostate, testis, liver, eye, kidney, 
adrenal glands, thyroid, heart, breast/mammary gland, 
uterus, skeletal muscle, specific regions of the brain 
(CNS) including spinal and bulbar motor neurons. 
Localisation 
Cytoplasm and nucleus. 
Function 
AR is a member of the steroid hormone receptor family 
of ligand-dependent nuclear receptors. AR functions 
include gene expression via actions as a DNA-binding  
transcription factor, cell cycle/proliferation regulation, 
cell-to-cell signaling, and intracellular signal 
transduction, leading to the regulation of biological 
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Layout of the AR gene, mRNA and protein with indicated regulatory regions. Borrowed from Litvinov, et al. 2003, with permission. 
processes such as development, cellular proliferation, 
differentiation and apoptosis. Some of the main target 
genes transcriptionally regulated by AR include AR, 
prostate specific antigen (PSA/hKlk3), hKlk2, hKlk4, 
prostate specific membrane antigen (PSMA), prostate 
stem cell antigen (PSCA), cell cycle regulator p27, 
vascular endothelial growth factor (VEGF), TMPRSS2, 
and Nkx3.1. 
Prostate organogenesis: The presence of AR is required 
in the mesodermal-derived embryonic urogenital sinus 
mesenchyme to trigger branching morphogenesis of 
endodermal-derived epithelial cells in the presence of 
androgens; subsequent AR expression in the 
developing epithelium drives secretory protein 
production. AR also plays an important role in the 
development of primary and secondary sexual 
characteristics, spermatogenesis, hormonal regulation 
of sexual drive, muscle growth, and male patterning of 
the brain. 
Recent identification of the gene fusion between the 5' 
end of the AR-regulated serine protease TMPRSS2 
(21q22.2) and the 3' end of ETS family of transcription 
factors ETV1 (7p21.3) and ERG (21q22.3) in a large 
frequency of prostate cancer cases raises new questions 
regarding AR function in prostate cancer. The gene 
rearrangement is thought to result in AR-induced 
expression of the suspected ETV1 or ERG oncogenes. 
Homology 
Zebrafish (Danio rerio), dog (Canis familiaris), African 
clawed frog (Xenopus laevis), chimpanzee (Pan 
troglodytes), mouse (Mus musculus), chicken (Gallus 
gallus), rat (Rattus norvegicus), rainbow trout 
(Oncorhynchus mykiss). 
No similarity-to-human data found for AR for:  
pig (Sus scrofa), cow (Bos taurus), fruit fly (Drosophila 
melanogaster), worm (Caenorhabditis elegans), baker's 
yeast (Saccharomyces cerevisiae), tropical clawed frog 
(Silurana tropicalis), African malaria mosquito 
(Anopheles gambiae), thale cress (Arabidopsis 
thaliana), green algae (Chlamydomonas reinhardtii), 
soybean (Glycine max), barley (Hordeum vulgare), 
tomato (Lycopersicon esculentum), rice blast fungus 
(Magnaporthe grisea), rice (Oryza sativa), sugarcane 
(Saccharum officinarum), loblolly pine (Pinus taeda), 
corn (Zea mays), wheat (Triticum aestivum), Alicante 
grape (Vitis vinifera), bread mold (Neurospora crassa), 
fission yeast (Schizosaccharomyces pombe), sea squirt 
(Ciona intestinalis), amoeba (Dictyostelium 
discoideum), A. gosspyii yeast (Ashbya gossypii), K. 
lactis yeast (Kluyveromyces lactis), medicago trunc 
(Medicago truncatula), malaria parasite (Plasmodium 
falciparum), schistosome parasite (Schistosoma 
mansoni), sorghum (Sorghum bicolor), toxoplasmosis 
(Toxoplasma gondii). 
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Mutations 
Germinal 
Germ-line loss of function mutations in AR result in 
non-lethal loss of AR expression, a hallmark of 
androgen insensitivity syndrome. Individuals with AIS 
have a Y chromosome and functional testes, which 
produce high levels of testosterone; however, they lack
male sex accessory organs, such as seminal vesicles 
and prostate, and are thus phenotypically female in 
both behavior and appearance. 
Somatic 
Various somatic AR mutations have been identified, 
some of which are associated with prostate cancer, 
including the T877A mutation in the prostate cancer 
LNCaP cell line, which permits AR activation by 
progestins, estrogen, adrenal androgens, and anti-
androgen hydroxyflutamide; however, the overall 
frequency of AR mutations in early, primary prostate 
cancer is <10%. 
Polymorphic CAG repeats in exon 1 encoding a 
polyglutamine tract of variable length give rise to AR 
peptides of varying lengths: shorter length (fewer CAG 
repeats) is associated with increased prostate cancer 
risk; increased length (greater CAG repeats) is 
associated with spinal and bulbar muscular atrophy and 
androgen insensitivity syndrome. For a more complete 





Androgenic alopecia, spinal and bulbar muscular 
dystrophy, androgen insensitivity syndrome due to AR 
mutations, benign prostatic hyperplasia, prostate 
adenocarcinoma. 
Prostate adenocarcinoma (PCa) 
Disease 
PCa is the most commonly diagnosed cancer in 
American men and the second leading cause of cancer-
related deaths. PCa predominantly occurs in the 
peripheral zone of the human prostate, with roughly 5 
to 10% of cases found in the central zone. Disease 
development involves the temporal and spatial loss of 
the basal epithelial compartment accompanied by 
increased proliferation and de-differentiation of the 
luminal (secretory) epithelial cells. PCa is a slow 
developing disease that is typically found in men 
greater than 40 years of age, with an increasing rate of 
occurrence with increasing age. 
Prognosis 
Serum PSA testing combined with digital-rectal exams 
(DRE) are used to screen for the presence of disease. 
Given a positive DRE exam, additional tests including 
needle core biopsies are taken to histologically asses  
disease stage and grade. Localized, prostate-restrict d 
disease is theoretically curable with complete removal 
of the prostate (radical prostatectomy). Patients with 
extra-prostatic disease are treated with chemotherapy, 
hormone (androgen ablation) therapy, radiation, and/or 
antiandrogens; however, no curative treatments are 
available for non-organ confined, metastatic disease. 
Cytogenetics 




Alterations in AR function are associated with the 
development of PCa due to a transition from paracrine 
AR signaling, traditionally involving the supporting 
mesenchyme instructing the terminal differentiation of 
the luminal epithelial cells, to autocrine AR signali g 
in luminal epithelial cells that promotes cell 
proliferation. Roughly 10% of PCa patients harbor AR
mutations, suggesting that the prevalence of AR 
mutations, clinically, is low. Mutations that increase the 
signaling promiscuity of AR, AR gene amplification, as 
well as alterations in proteins that regulate AR 
levels/function contribute to de-regulated AR signaling. 
Benign prostatic hyperplasia (BPH) 
Disease 
Benign growth of the prostate, primarily occurring in 
the transitional zone of the prostate, results in ur ary 
obstruction and lower urinary tract symptoms. AR 
function is associated with increased rates of epith lial 
cell proliferation, leading to increased size of the 
prostate gland. Originally thought of as benign prostatic 
hypertrophy, BPH has since been correctly 
characterized as a hyperplastic condition. 
Prognosis 
Patients with BPH are primarily treated with 2 types of 
agents to help reduce the size of the prostate, including 
Alpha-blockers: Flomax (tamsulosin), Uroxatral 
(alfuzosin), Hytrin (terazosin), Cardura (doxazosin); 
and 5-Alpha Reductase Inhibitors: Avodart 
(dutasteride), Proscar (finasteride). For symptoms 
unabated by medications, minimally invasive 
procedures: Transurethral microwave therapy (TUMT) 
and Transurethral needle ablation (TUNA) exist. More 
invasive surgeries: Transurethral resection of the 
prostate (TURP), Open prostatectomy (open surgery), 
Laser surgery, Transurethral incision of the prostate 
(TUIP) are available. 
Oncogenesis 
Occurring in the transitional zone of the prostate, it is 
currently believed that BPH does not lead to or initiate 
the development of PCa. 
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Spinal and bulbar muscular atrophy 
Note: X-linked recessive form of spinal muscular 
atrophy. 
Disease 
Spinal and bulbar muscular atrophy (SBMA, SMAX1), 
which is also known as Kennedy disease (KD), is 
caused by a trinucleotide CAG repeat expansion in 
exon 1 of the AR gene, resulting in decreased AR 
mRNA and protein levels. SBMA patients carry 38 to 
62 CAG repeats; healthy individuals have 10 to 36. 
Prognosis 
SBMA is a neurodegenerative disease resulting in slow, 
progressive limb and bulbar muscle weakness, 
characterized by muscle atrophy due to neuron 
dysfunction. Also can cause gynecomastia. Current 
therapies include androgen deprivation therapy to curb 
the effects of pathologic AR signaling. 
Androgen insensitivity syndrome (AIS) 
Note: X-linked recessive disorder. 
Disease 
Androgen insensitivity syndrome (AIS), testicular 
feminization syndrome (TFM). Affected males have 
female external genitalia, female breast development, 
blind vagina, absent uterus and female adnexa, and 
abdominal or inguinal testes, despite a normal male 
(2A + XY) karyotype. Caused by mutations in the gene 
for the androgen receptor. 
References 
Hiort O, Holterhus PM, Nitsche EM. Physiology and 
pathophysiology of androgen action. Baillieres Clin Endocrinol 
Metab 1998;12(1):115-132. 
Abate-Shen C, Shen MM. Molecular genetics of prostate 
cancer. Genes Dev 2000;14(19):2410-2434. 
Hyytinen ER, Haapala K, Thompson J, Lappalainen I, Roiha M, 
Rantala I, Helin HJ, Jänne OA, Vihinen M, Palvimo JJ, Koivisto 
PA. Pattern of somatic androgen receptor gene mutations in 
patients with hormone-refractory prostate cancer. Lab Invest 
2002;82:1591-1598. 
Shang Y, Myers M, Brown M. Formation of the androgen 
receptor transcription complex. Mol Cell 2002;9(3):601-610. 
Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for 
prostate cancer therapy a gain of function in androgen receptor 
signaling?. J Clin Endocrinol Metab 2003;88(7):2972-2982. 
(Review). 
Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, 
Hayward SW, Wang YZ, Donjacour AA, Kurita T. Hormonal, 
cellular, and molecular regulation of normal and neoplastic 
prostatic development. J Steroid Biochem Mol Biol 
2004;92(4):221-236. 
Katsuno M, Banno H, Suzuki K, Takeuchi Y, Sobue G. 
Paradigm shift in clinical trials for neurodegenerative diseases. 
Brain Nerve 2007;59(4):367-374. 
This article should be referenced as such: 
D'Antonio J. AR (androgen receptor (dihydrotestosterone 
receptor; testicular feminization; spinal and bulbar muscular 
atrophy; Kennedy disease)). Atlas Genet Cytogenet Oncol 
Haematol.2008;12(5):358-361. 
 
 
